sarcoma patients with worse survival rates than p53 mutational status. We propose a novel role for alternative splicing of HDMX, whereby it serves as a mechanism by which HDMX protein levels are reduced in cancer cells that have already inhibited p53 activity. Alternative splicing of HDMX could therefore serve as a more effective biomarker for p53 pathway attenuation in cancers than p53 gene mutation.
Introduction
Osteosarcoma is the most common primary bone malignancy in children and adolescents, occurring mostly in patients between 10 and 25 years of age and found in the rapid growth areas of the long bones (1) . The vast majority of osteosarcomas arise without a clear hereditary component, with the exception of a small subset including individuals with the Li-Fraumeni and progeria syndromes. Overall long-term (5-year) survival for patients with non-metastatic osteosarcomas has increased from 10 to 65% over the past 20 years, due to improved surgical techniques and multidrug chemotherapy, but further improvement is needed (2) . Indeed, 25-50% of patients will relapse or metastasize and 5-year survival rate for metastatic osteosarcomas is only 10 to 20% (3, 4) . It is clear that additional therapies are required in order to increase the survival of osteosarcoma patients.
In approximately 50% of all human cancers mutations are found in the TP53 gene, which encodes the tumor suppressor protein p53 (5-7). Indeed, it has been clearly shown that in many of the remaining 50% of cancers, the activity of the wild type p53 protein is greatly attenuated (8) . In high-grade osteosarcoma, mutations in the p53 gene are found in only 20% of the tumors (9) (10) (11) . However, the genomic region that encodes for a key negative regulator of p53, HDM2 (12, 13) , was found to be amplified in 10-35% of osteosarcomas and these amplifications were shown to be mutually exclusive to p53 mutations (9) (10) (11) 14) .
In many of the studies that were aimed at determining the importance of the inactivation of the p53 pathway during the progression of osteosarcoma, only p53 mutational status was studied and the level of HDM2 protein expression was not included, resulting in the possible underestimation of the influence of p53 inactivation on prognosis. Moreover, the somatic mutation or alteration of other crucial effectors of p53 activity has also been under-studied in osteosarcoma. For example, the oncogene HDMX is a close homolog of HDM2 and encodes a protein product, which also clearly inhibits p53 activity (15, 16) . In several tumor types, overexpression and amplification of HDMX has been shown both in tumors (17, 18) and tumor-derived cell lines and is primarily found in tumors that have retained wild-type p53 (19) . Indeed, two tumor types that have a very low frequency of p53 gene mutation (retinoblastomas and Ewing sarcomas) have demonstrated elevated HDMX expression (20, 21) .
In sarcomas, amplification of the HDMX gene has been found in both soft tissue sarcomas (STS, 16 to 17%) and osteosarcomas (35%) (14, 22) . Bartel et al. demonstrated a significant association between HDMX amplification and poor prognosis after initial STS diagnosis (22) . In addition, they showed that the mRNA expression of an alternative splice variant of Hdmx, HDMX-S, is upregulated in 14% of STS, and that an increase in the ratio of the transcript levels of the splice variant over full length (the HDMX-S/HDMX-FL ratio)
correlates with a higher tumor grade at diagnosis and decreased overall survival (22) . The HDMX-S/HDMX-FL ratio was also found to be increased in high-grade glioblastomas (17) and papillary thyroid carcinomas (23) . The HDMX-S transcript results from the exclusion of exon 6 (24), resulting in a truncated protein essentially consisting of the p53-binding domain which, in overexpression studies, was found to be stronger inhibitor of p53 shown to bind to and inhibit p53 more efficiently (24) . Although studies such as these suggest an oncogenic role for the HDMX-S protein, no conclusive evidence has been published to date to suggest that the protein is produced and active in cells (25) . Indeed, our previous work suggests that an increase in the HDMX-S/HDMX-FL ratio associates primarily with reduced levels of full length HDMX protein (25) .
Here, we report further on the alterations in the HDMX-S/HDMX-FL ratio in relation with p53 status and cancer progression. The results indicate that changes in the HDMX-S/HDMX-FL ration could serve as a more effective biomarker for p53 pathway attenuation in cancers than p53 gene mutation.
Research. 
Materials and Methods

Patient Material
Osteosarcoma cohort
Clinicopathological data of 51 osteosarcoma patients are shown in Supplementary Table S1 . Part of the samples were previously described (26) .
Biopsies were taken before pre-operative chemotherapeutics were administered.
The differences in response to chemotherapy were classified as good or poor, using the Huvos criteria (27) . All tissue samples were handled according to the
National Ethical Guidelines ('Code for Proper Secondary Use of Human Tissue in
The Netherlands', Dutch Federation of Medical Scientific Societies).
Soft Tissue Sarcoma Cohort
The clinicopathological data of the 157 soft tissue sarcoma patients included in this study are shown in Supplementary Table S2 . A subset was previously described (22) . Tumor samples were taken before adjuvant radio-and/or chemotherapeutics were administered. The study adhered to national regulations on ethical issues and was approved by the local ethical committee. All patients gave written and informed consent (Department of Surgery 1, University of Leipzig, Germany).
Cell Culture and Reagents
Cell lines were maintained in RPMI supplemented with 10% fetal bovine serum and antibiotics. Most of the osteosarcoma cell lines have been described recently, including their genotyping and detailed methods on p53 sequencing Band intensities were quantified using Odyssey 2.1 analysis software (LI-COR Biosciences, Lincoln, Nebraska USA).
NCI60 cell lines
The cDNAs for the NCI60 cell lines panel were derived from RNAs obtained from for known cancer mutations, and variations in short tandem repeats. Much of these data can be found on the DTP web-site. The mRNA levels of HDMX-S and HDMX-FL were determined as described above. Measurements of HDM2 transcript levels were performed by qRT-PCR using commercially available RoboGene®MDM2 cDNA quantification module, with ABI PRISM 7000 Sequence Detection System. HDM2 measurements were normalised to GAPDH transcript levels.
Soft tissue sarcomas
HDMX-FL and HDMX-S transcript levels were measured by quantitative real-time RT-PCR as described (22) . Briefly, the reactions were carried out on a Rotor- 
Protein extraction, Western blotting and Antibodies
Protein extraction and immunoblotting were performed as described previously (33) . Anti-Hdmx and anti-USP7 (A300-287A,A300-033A; Bethyl Laboratories, Montgomery, TX), anti-p53 PAb1801 and DO-1, anti-HDM2 antibodies 4B2 (34) and SMP14 (Santa Cruz Biotechnology, Santa Cruz, CA). Secondary antibodies goat-anti-mouse-HRP and goat-anti-rabbit-HRP were obtained from Jackson Laboratories. 
Statistical Analysis
The GraphPad Instat version 3.06 software was used to compare means. The Kaplan Meier and Cox multivariate regression survival analyses and the analyses of contingency tables were performed using the SPSS 19.0 software. Statistical significance was regarded as p< 0.05.
Results
The HDMX-S/HDMX-FL ratio in osteosarcoma
To further explore the importance of the p53 pathway during the progression of osteosarcoma, we initially analyzed the HDMX-S/HDMX-FL ratio and its association with HDMX protein levels in 22 osteosarcoma cell lines. The levels of HDMX-S and HDMX-FL mRNA were determined in logarithmically growing cells for all 22 osteosarcoma cell lines and 1 osteoblast. Semi-quantitative PCR was performed using primers designed to amplify exons 3 to 8 (Fig. 1A) . The intensities of the bands for HDMX-S and HDMX-FL were quantified and normalized to GAPDH expression levels ( Fig. 1B) and results are summarized in Supplementary Table S3 . The protein levels of HDMX were also determined from logarithmically growing cells (Fig. 1C) . The intensities of the band corresponding to HDMX were quantified and normalized to USP7 levels (Supplementary Table S3 ). The HDMX-S/HDMX-FL ratios varied from 0.39 to 3.18 with a median of 1.5, a standard deviation of 0.7 and a normal distribution ( Fig.2A) . Interestingly, the HDMX-S/HDMX-FL ratio significantly negatively correlated with the measured HDMX protein levels (p=0.004, Fig. 2B ).
Specifically, those five cells with the highest HDMX-S/HDMX-FL ratios had 9.5 fold less HDMX protein than those five cells with the lowest ratios (t-test, p= 0.0238, Fig. 2C ).
Research. In order to explore the potential association of the HDMX-S/HDMX-FL ratio with osteosarcoma progression and survival we studied 51 high-grade osteosarcoma patients from Germany, Holland and Italy (Supplementary Table S1 ). The patients consisted of 32 males and 19 females with an average age of diagnosis of 17.5 years, ranging from 3-58 years. The levels of HDMX-S and HDMX-FL were determined in biopsies that were taken before pre-operative chemotherapy.
The level of each transcript was determined in 49 of the samples ( Table S3 ). The p53 status of all 22 osteosarcoma cell lines was determined using a combination of direct sequencing, p53 mRNA measurements and measurements of the response of each cell line to Nutlin-3, a small molecule inhibitor of the p53-HDM2 interaction that activates p53 signalling (35) . A cell line was only deemed to have functional wild type p53 if no mutations were found in exons 3 to 11, it expressed detectable levels of p53 mRNA and protein, and responded to Nutlin-3 treatment, as measured by the determination of p53 and HDM2 protein levels ( Supplementary Fig. S1A ), reduced survival ( Supplementary   Fig. S1B ). and inhibition of cell cycle progression (Supplementary Fig. S1C ). Of the 22 cell lines, only 6 lines were deemed to be wild type for p53 (Supplementary Table S3 
Mann-Whitney test, Table 1 Figure 4B) . Interestingly, the HDMX-S/HDMX-FL ratio significantly negatively correlated with measured HDMX protein levels (p=2.28x10 -8 , Fig. 4C ). Furthermore, when the cells were ranked by the measured HDMX-S/HDMX-FL ratios and subsequently divided into almost equal groups of 9, the groups with increasing ratios had significantly decreasing HDMX protein levels (Kruskal-Wallis Test, p=0.0001, Fig. 4D ).
Specifically, the 9 cell lines with the highest HDMX-S/HDMX-FL ratios had 9.87 fold less HDMX protein than the 9 cell lines with the lowest ratios (Mann-Whitney Test, p= 0.0002).
The 8 breast cancer cell lines with wild-type p53 contained significantly lower Fig. S2A ) and the levels of HDM2 mRNA normalised to GAPDH using qRT-PCR (Supplementary Table S6 ).
HDMX-S/HDMX-FL
The HDMX-S/HDMX-FL ratios varied from 0 to 18.65, with a median of 1.25 and a standard deviation of 3.3. The distribution of the HDMX-S/HDMX-FL ratios, similarly to the breast cancer cell panel and osteosarcoma patients, was not normal (Fig. Supplementary S2B) . Interestingly, we found that the 14 cell lines with wild-type p53 had significantly lower HDMX-S/HDMX-FL ratios than the remaining 36 cell lines lacking functional p53 (p=0.0227, Mann-Whitney Test, Table 1 ). Furthermore, a similar significant trend was observed when we compared HDMX-S/HDMX-FL ratios in the wild-type p53 cell lines with either high or low levels of HDM2 mRNA. Specifically, the 7 cell lines with the lowest HDM2 mRNA levels had significantly lower HDMX-S/HDMX-FL ratios than the 7 cell lines with the highest levels of HDM2 (p=0.0364, Mann-Whitney Test, 1-tailed, Table 1 ).
Together, these observations made in three cell panels comprising a total of 115 different cell lines, lend support to a model that higher HDMX-S/HDMX-FL ratios, and therefore lower HDMX protein levels, arises in cancer cells that have attenuated p53 signalling through alterations of key p53 pathway genes. Indeed, we observed that the 27 cell lines with wild-type p53 in the three panels had significantly lower HDMX-S/HDMX-FL ratios than the 79 cell lines lacking functional p53 (p=0.0001, Mann-Whitney Test, Table 1 ). Furthermore, in the 27 wild-type p53 cell lines, the 13 lines with the lowest HDM2 mRNA levels had 
The HDMX-S/HDMX-FL ratio and p53 mutation as prognostic markers
Thus far in cells, we have observed that the cancer lines with higher HDMX-S/HDMX-FL ratios have significantly higher frequencies of two common p53 pathway mutations, namely p53 gene mutation and HDM2 overexpression (Table 1, Figure 5 ). Inhibition of p53 signalling through p53 mutation has clearly been shown to have prognostic value in multiple cancers (36) . If the proposed model is true, the HDMX-S/HDMX-FL ratio could potentially serve as a more effective prognostic biomarker than p53 gene mutation, because alterations of other key p53 pathway genes that result in p53 pathway attenuation could be captured simultaneously. To begin to explore this possibility, we compared the prognostic value of either p53 tumor mutation or the HDMX-S/HDMX-FL in another tumor type that is clearly surveyed by p53 signalling, namely soft tissue sarcoma (STS), where an increase of the HDMX-S/HDMX-FL ratio has been shown to associate with altered survival (22) .
We studied a cohort of 157 soft tissue sarcoma patients from Germany (Supplementary Table S2 ). We were able to receive ample tumor material from 80 patients for the HDMX transcript analysis and the patients consisted of 36 males and 44 females. The levels of HDMX-S and HDMX-FL were determined, as described in the materials and methods, in tumor samples that were taken before therapy . The levels of each transcript were determined and normalized to status were determined, we observed that the tumors with higher HDMX-S transcript levels than HDMX-FL were significantly enriched for p53 mutations (p=0.0337, Fisher's exact Test, one-sided, Fig. 6A ). The p53 mutation status alone could not effectively serve as a prognostic factor. Patients that had retained wild-type p53 in their sarcomas had longer survival times than those with mutant p53, although the difference was not significant (p=0.469, Logrank Test, Fig. 6B ; Supplementary Fig. S3A) . However, the patients whose tumors had more HDMX-S than HDMX-FL transcripts had significantly shorter overall survival than those with equal or lower HDMX-S transcript levels (p=0.024 Logrank Test, Fig. 6C ; Supplementary Fig. S3B,S3C ) with a 5.746-fold higher risk of tumor-related death (p=0.01, Fig. 6D ).
Discussion
In this study, we began with the aim of further exploring the importance of the p53 pathway during the progression of osteosarcoma, through the analysis of the HDMX-S/HDMX-FL ratio and its association with HDMX protein levels in 22 osteosarcoma cell lines, as well as cancer progression and survival in 51 osteosarcoma patients. Previously, we and others had reported increased mRNA expression of HDMX-S in various cancers (17, 22, 23) . Interestingly, many tumors that showed increased HDMX-S mRNA levels had less HDMX full-length RNA and protein (22, 23) , and correlated with later tumor stage and poorer CAN-12-0215 survival. For example, we demonstrated that even in cells expressing predominantly HDMX-S mRNA, only full length HDMX protein could be detected ( Fig. 4A and (25) ). We propose that the HDMX-S protein is very unstable or inefficiently translated and, therefore, is unlikely to play an important, dominant role in cell proliferation. Here, we further showed that as the HDMX-S/HDMX-FL ratio increased, HDMX full-length protein decreased in the 22 osteosarcoma cell lines and the 37 breast cancer cell lines studied (Figures 1, 2 and 4) . For example, the osteosarcoma cell lines with the highest HDMX-S/HDMX-FL ratio expressed up to 9.5 fold less HDMX full length protein.
In this study we went on to explore the potential association of the HDMX-S/HDMX-FL ratio with osteosarcoma progression, as we and others had previously demonstrated (17) . Here, we studied 51 high-grade osteosarcoma patients and, strikingly, found that high HDMX-S/HDMX-FL ratios correlated with faster metastatic progression (Fig. 4) . Specifically, over two years, 62% of those with the highest HDMX-S/HDMX-FL ratios had presented with a metastasis, compared to only 8% of those with the lowest ratios. Interestingly, a subset of the cell lines utilized in this study had been previously analysed for in vivo growth characteristics, including the capacity to metastasize (40). One of the tested cell lines was found to produce metastases in mice, HOS-143B, whereas the parental HOS cell line did not. Intriguingly, and in line with our observations in the patient cohort, we found a dramatically increased HDMX-S/HDMX-FL ratio and significantly decreased HDMX protein levels in HOS-143B cells compared to HOS cells (Fig. 1B and C) .
Our observations in an osteosarcoma cell line panel and patient cohort suggest that the HDMX-S/HDMX-FL ratio positively correlates with less HDMX protein expression, as proposed earlier (25) , and faster metastatic progression, as well as a trend to worse overall survival. In this study, we proposed that a reason why a cancer cell would not retain the oncogenic activity of HDMX is because it has already inhibited p53 signalling by mutations of other key regulatory genes in the The second p-value is derived from a logrank test comparing the patients with higher ratios to those with low ratios, as depicted by the * symbol. Fig. 6D Predicted survival curves for patients with different HDMX-S/HDMX-FL ratios (n=64) derived from a Cox multivariate regression analysis that was adjusted to the known independent prognostic factors of soft tissue sarcomas that included tumor stage, resection type, tumor location and tumor type. The p-value depicted on the plot is derived through the comparison of the patients with higher ratios to those with low ratios, as is depicted by the * symbol. 
